Lapatinib in the treatment of breast cancer

References

• Jensen EV, DeSombre ER, Jungblut PW. Estrogen receptors in hormone-responsive tissues and tumors. In: Endogenous Factors Influencing Host–Tumor Balance. Wissler RW, Dao TL, Wood S Jr (Eds). University of Chicago Press, IL, USA 15–30 (1967).
   Google Scholar
• Nowell PC. The minute chromosome (Phl) in chronic granulocytic leukemia. Blut8, 65–66 (1962).
   PubMedGoogle Scholar
• Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235(4785), 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.353(16), 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353(16), 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Montemurro F, Donadio M, Clavarezza M et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist11(4), 318–324 (2006).
   PubMed Web of Science ®Google Scholar
• Bartsch R, Wenzel C, Hussian D et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer6, 63–68 (2006).
   PubMed Web of Science ®Google Scholar
• Garcia-Saenz JA, Martin M, Puente J et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin. Breast Cancer6, 325–329 (2005).
   PubMedGoogle Scholar
• Gelmon KA, Mackey J, Verma S et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin. Breast Cancer5(1), 52–58 (2004).
   PubMedGoogle Scholar
• Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med.355(26), 2733–2743 (2006).
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell103(2), 211–225 (2000).
   PubMed Web of Science ®Google Scholar
• Garrett TP, McKern NM, Lou M et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation poised to interact with other ErbB receptors. Mol. Cell11(2), 495–505 (2003).
   PubMed Web of Science ®Google Scholar
• Jones FE, Stern DF. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene18(23), 3481–3490 (1999).
   PubMed Web of Science ®Google Scholar
• Jones FE, Welte T, Fu XY, Stern DF. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J. Cell Biol.147(1), 77–87 (1999).
   PubMed Web of Science ®Google Scholar
• Harris AL, Nicholson S, Sainsbury R, Wright C, Farndon J. Epidermal growth factor receptor and other oncogenes as prognostic markers. Natl Cancer Inst. Monogr.11, 181–187 (1992).
   Google Scholar
• Di Marco E, Pierce JH, Fleming TP et al. Autocrine interaction between TGF α and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene4(7), 831–838 (1989).
   PubMed Web of Science ®Google Scholar
• Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J. Clin. Oncol.11(10), 1936–1942 (1993).
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol.20(3), 719–726 (2002).
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that progressed after chemotherapy for metastatic disease. J. Clin. Oncol.17(9), 2639–2648 (1999).
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol.20(7), 1800–1808 (2002).
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Harris LN, Marcom PK et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter Phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J. Clin. Oncol.21(15), 2889–2895 (2003).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11), 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Wood ER, Truesdale AT, McDonald OB et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res.64(18), 6652–6659 (2004).
   PubMed Web of Science ®Google Scholar
• Burris HA III, Hurwitz HI, Dees EC et al. Phase I study, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol.23(23), 5305–5313 (2005).
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist9(Suppl. 3), 10–15 (2004).
   PubMed Web of Science ®Google Scholar
• Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. All erbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem.271(9), 5251–5257 (1996).
   PubMed Web of Science ®Google Scholar
• Lenferink AEG, Pinkas-Kramarski R, van de Poll MLM et al. Differential endocytic routing of homo- and hetero-dimeric erbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J.17(12), 3385–3397 (1998).
   PubMed Web of Science ®Google Scholar
• Bence AK, Anderson EB, Halepota MA et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR–ErbB2 inhibitor, in healthy subjects. Invest. New Drugs23(1), 39–49 (2005).
   PubMed Web of Science ®Google Scholar
• Geyer CE, Martin A, Newstat B et al. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): genomic and updated efficacy data. Proc. Am. Soc. Clin. Oncol.25(Suppl. 18), 1035 (2007).
   Google Scholar
• Sonpavde G. Lapatinib plus capecitabine in breast cancer. N. Engl. J. Med.356(14), 1471–1472 (2007).
   PubMedGoogle Scholar
• Geyer CE, Forster J, Cameron MD. Lapatinib plus capecitabine in breast cancer. N. Engl. J. Med.356(14), 1471–1472 (2007).
   PubMedGoogle Scholar
• Stein SH, Gomez HL, Chavez MA et al. Interim results of a Phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with FISH-amplified advanced or metastatic breast cancer. Eur. J. Cancer3(Suppl.), 78 (2005).
   Google Scholar
• Perez EA, Byrne JA, Hammond IW et al. Cardiac safety experience in 3127 patients treated with lapatinib. Ann. Oncol.17(Suppl. 9), 1420 (2006).
   Google Scholar
• Kannel WB. Incidence and epidemiology of heart failure. Heart Fail. Rev.5(2), 167–173 (2000).
   PubMedGoogle Scholar
• Fujimoto-Ouchi K, Sekiguchi F, More I. Preclinical study of continuous administration trastuzumab as combination therapy after disease progresses with trastuzumab monotherapy. Proc. Am. Assoc. Cancer Res.46, 5062 (2005).
   Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351(4), 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol.23(19), 4265–4274 (2005).
   PubMed Web of Science ®Google Scholar
• Altaha R, Crowell E, Hobbs G, Higa G, Abraham J. Increased risk of brain metastasis in patients with HER-2/neu-positive breast carcinoma. Cancer103(3), 442–443 (2005).
   PubMed Web of Science ®Google Scholar
• Stemmler J, Kahlert S, Siekiera W et al. Brain metastases (BM) in patients treated with trastuzumab for HER overexpressing metastatic breast cancer (MBC): incidence and survival. J. Clin. Oncol.23(Suppl. 16), Abstract 1568 (2005).
   Google Scholar
• Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J. Clin. Oncol.24(Suppl. 18, Part I) (2006) (Abstract 503).
   Web of Science ®Google Scholar
• Lin NU, Dieras V, Paul D et al. EGF105084, a Phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). Proc. Am. Soc. Clin. Oncol.25(Suppl. 18), 1012 (2007).
   Google Scholar
• Campone M, Bourbouloux E, Fumoleau P. Cardiac dysfunction induced by trastuzumab. Bull. Cancer91(Suppl. 3), 166–173 (2004).
   PubMedGoogle Scholar
• Grazette LP, Boecker W, Matsui T et al. Inhibition of erbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J. Am. Coll. Cardiol.44(11), 2231–2238 (2004).
   PubMed Web of Science ®Google Scholar
• Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res.61(24), 8887–8895 (2001).
   PubMed Web of Science ®Google Scholar
• ECOG E1100: a Phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2). Clin. Adv. Hematol. Oncol.1, 237 (2003).
   PubMedGoogle Scholar
• Baselga J, Albanell J, Ruiz A et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J. Clin. Oncol.23(23), 5323–5233 (2005).
   PubMed Web of Science ®Google Scholar
• Rampaul RS, Pinder SE, Nicholson RI, Gullick WJ, Robertson JF, Ellis IO. Clinical value of epidermal growth factor receptor expression in primary breast cancer. Adv. Anat. Pathol.12(5), 272–273 (2005).
   Google Scholar
• Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin. Cancer Res.8(11), 3454–3460 (2002).
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Jonat W, Fasching P et al. A multicentre Phase II study on geftinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res. Treat.89(2), 165–172 (2005).
   PubMed Web of Science ®Google Scholar
• Modi S, D’Andrea G, Norton L et al. A Phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin. Breast Cancer7(3), 270–277 (2006).
   PubMed Web of Science ®Google Scholar
• Alimandi M, Romano A, Curia MC et al. Cooperative signaling of erbB3 and erbB2 in neoplastic transformation and human mammary carcinomas. Oncogene10(9), 1813–1821 (1995).
   PubMed Web of Science ®Google Scholar
• Kokai Y, Myers JN, Wada T et al. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell58(2), 287–292 (1989).
   PubMed Web of Science ®Google Scholar
• Xia W, Liu L-H, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW72016. Oncogene23(3), 646–653 (2004).
   PubMed Web of Science ®Google Scholar
• Segatto O, King CR, Pierce JH, DiFiore PP, Aaronson SA. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol. Cell Biol.8(12), 5570–5574 (1988).
   PubMed Web of Science ®Google Scholar
• Colomer R, Montero S, Lluch A et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin. Cancer Res.6(6), 2356–2362 (2000).
   PubMed Web of Science ®Google Scholar
• Molina MA, Saez R, Ramsey et al. NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin. Cancer Res.8(2), 347–353 (2002).
   PubMed Web of Science ®Google Scholar
• Hirata A, Hosoi F, Miyagawa M et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res.65(10), 4253–4260 (2005).
   PubMed Web of Science ®Google Scholar
• Anido J, Matar P, Albanell J et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER-overexpressing breast cancer cells. Clin. Cancer Res.9(4), 1274–1283 (2003).
   PubMed Web of Science ®Google Scholar
• Gamett DC, Pearson G, Cerione RA, Friedberg I. Secondary dimerization between members of the epidermal growth factor receptor family. J. Biol. Chem.272(18), 12052–12056 (1997).
   PubMed Web of Science ®Google Scholar
• Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science267(5205), 1782–1788 (1995).
   PubMed Web of Science ®Google Scholar
• Wang SC, Lien HC, Xia W et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor erbB-2. Cancer Cell6(3), 251–261 (2004).
   PubMed Web of Science ®Google Scholar